People · Operator
Named in public records as an officer, director or promoter · active 2015–2015 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Calimmune, Inc. | — | Biotechnology | Series B | $15.9M | $629.2M | 2015 |
David H. Donabedian, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David H. Donabedian, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Kolchinsky | 1 | 8 |
| Harry A. George | 1 | 3 |
| Jon Faiz A. Kayyem, Ph.D. | 1 | 1 |
| Louis Breton | 1 | 1 |
| David Baltimore, Ph.D. | 1 | 1 |
| Bhavin H. Raval | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.